Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is an anticonvulsant presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures and is used as adjunctive therapy in patients with epilepsy. GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that targets neuronal excitability in seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing therapy. Adjunctive therapy for epilepsy: improves overall seizure control in combination with other antiepileptic agents. Focal seizures: helps manage seizures originating from a specific brain region.

Lacosamide may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Somnolence

Serious or Rare Side Effects: - PR‑interval prolongation or other cardiac conduction abnormalities - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including rash and angioedema - Elevated liver enzymes - Respiratory depression in susceptible individuals

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver function tests. - Concomitant antiepileptic drugs: assess for possible pharmacokinetic interactions. - History of cardiac conduction disorders: obtain baseline ECG and monitor periodically. - Pregnancy: safety data are limited; discuss potential risks with the patient. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may lower lacosamide plasma concentrations. - Phenytoin: can reduce lacosamide effectiveness. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system depression. - Other sodium‑channel blockers (e.g., lamotrigine): additive effects on cardiac conduction. - Hormonal contraceptives: potential alteration of contraceptive efficacy.